跨文化适应为意大利语并验证法国言语障碍评估-2.
Cross-cultural adaptation into Italian and validation of the Frenchay dysarthria assessment - 2.
机构信息
Villa Beretta Rehabilitation Center, Valduce Hospital, Costa Masnaga, Lecco, Italy.
Department of Biomedical and Clinical Sciences "Luigi Sacco, " University of Milan, Milan, Italy -
出版信息
Eur J Phys Rehabil Med. 2022 Jun;58(3):342-351. doi: 10.23736/S1973-9087.21.07029-5. Epub 2021 Sep 9.
BACKGROUND
A comprehensive evaluation of dysarthria is required to make an accurate differential diagnosis with other communication disorders and plan effective rehabilitation programs. The Frenchay Dysarthria Assessment-2 (FDA-2) is a valid, reliable and widely used protocol for the assessment of dysarthria. An Italian version of the FDA-2 is currently lacking.
AIM
To perform a cross-cultural adaptation of the FDA-2 in Italian and to validate the Italian version of the FDA-2.
DESIGN
Validation study.
SETTING
Inpatient rehabilitation center.
POPULATION
69 patients with dysarthria and 112 healthy controls.
METHODS
The FDA-2 was translated and cross-culturally adapted to Italian. The validation study was carried out in 4 steps: (1) 42 audio-recorded samples of FDA-2 items from 11 patients with dysarthria were independently assessed by 7 speech and language pathologists for interrater reliability and re-assessed after 6 weeks for intrarater reliability; (2) 11 patients were simultaneously assessed by 3 speech and language therapists for interrater reliability of the whole Italian version of the FDA-2 and re-assessed within 24 hours for test-retest reliability; (3) the Italian version of the FDA-2 was administered to 112 healthy volunteers to gain normative data; (4) 49 patients with different types of dysarthria were assessed using the Italian version of the FDA-2, the Therapy Outcome Measure impairment scale and the Robertson Profile for the validity analysis.
RESULTS
Interrater and intrarater reliability ranged from good to excellent (ICC >0.75) except for 3 audio-recorded items. The overall protocol demonstrated excellent (ICC >0.9) inter-rater and test-retest reliability for all the sections and the total score. Normative data were gained for 6 age groups. For the validity analysis, a statistically significant difference was found between dysarthric patients and healthy subjects for all sections and the total score. The FDA-2 significantly correlated to the therapy outcome measure (r=0.75) and the Robertson Profile (r=0.81).
CONCLUSIONS
The Italian version of the FDA-2 yield satisfactory reliability and validity, comparable to the psychometric properties of the original version.
CLINICAL REHABILITATION IMPACT
Speech and language pathologists can rely on a valid and reliable tool in Italian for the assessment of dysarthria in both clinical and research practice.
背景
为了对其他交流障碍进行准确的鉴别诊断并制定有效的康复计划，需要对构音障碍进行全面评估。Frenchay 构音障碍评估-2（FDA-2）是一种评估构音障碍的有效、可靠且广泛使用的方案。目前缺乏 FDA-2 的意大利版本。
目的
将 FDA-2 进行跨文化适应转化为意大利语，并验证 FDA-2 的意大利版本。
设计
验证研究。
设置
住院康复中心。
人群
69 名构音障碍患者和 112 名健康对照者。
方法
FDA-2 被翻译并跨文化适应为意大利语。验证研究分 4 个步骤进行：（1）11 名构音障碍患者的 42 个 FDA-2 项目的音频记录样本由 7 名言语语言病理学家进行独立评估，以评估组内可靠性，并在 6 周后重新评估以评估组内可靠性；（2）3 名言语语言治疗师同时对 11 名患者进行整个 FDA-2 的意大利语版本的组内可靠性评估，并在 24 小时内进行重测以评估测试-重测可靠性；（3）对 112 名健康志愿者进行意大利语版 FDA-2 的测试，以获取正常数据；（4）使用意大利语版 FDA-2、治疗结果测量损伤量表和 Robertson 分析图对 49 名不同类型构音障碍患者进行评估，以进行有效性分析。
结果
除 3 个音频记录项目外，组内和组内可靠性均为良好至优秀（ICC＞0.75）。总体方案在所有部分和总分上均表现出优异的（ICC＞0.9）组间和测试-重测可靠性。获得了 6 个年龄组的正常数据。对于有效性分析，在所有部分和总分上，构音障碍患者与健康受试者之间存在统计学显著差异。FDA-2 与治疗结果测量（r=0.75）和 Robertson 分析图（r=0.81）显著相关。
结论
意大利语版 FDA-2 具有令人满意的可靠性和有效性，与原始版本的心理测量特性相当。
临床康复影响
言语语言病理学家可以在意大利语中依赖一种有效的、可靠的工具，在临床和研究实践中评估构音障碍。
Zotero 插件